Infiltración periarticular y ácido tranexámico tópico para control de pérdida sanguínea en artroplastia total de rodilla / Periarticular injection and topical tranexamic acid for blood loss control in total knee arthroplasty

Introducción La pérdida sanguínea durante el remplazo total de rodilla es una de las principales variables que influyen en los resultados de esta cirugía para lo cual se han implementado varios métodos para reducirla. Objetivo Cuantificar el cambio en el hematocrito y hemoglobina a las 24 horas postoperatorias en pacientes a quienes se les realizó reemplazo total de rodilla primario entre marzo del 2016 y agosto del 2017. Metodología Se realizó un estudio observacional a partir de una cohorte retrospectiva. Los criterios de inclusión fueron aquellos pacientes a quienes se les realizó reemplazo total de rodilla primaria con infiltración periarticular con bupivacaina con epinefrina, ketorolaco y morfina e intrarticular con ácido tranexámico. Se midieron hemoglobina y hematocrito pre y post operatorio, cálculo de pérdida sanguínea y transfusiones. Resultados Se analizaron un total de 159 reemplazos totales de rodilla (75 prótesis convencionales, 84 prótesis navegadas). El porcentaje de transfusión fue de 0,69% (1 paciente). La disminución del hematocrito promedio fue de 7,36% y la disminución de la hemoglobina de 2,49 gr/dl para una pérdida sanguínea calculada de 780ml. Se usó torniquete en 147 pacientes. Discusión La combinación de uso de torniquete, infiltración periarticular e intra articular de ácido tranexamico reduce la pérdida sanguínea y la necesidad de tranfusiones.

Background The blood loss during the total knee replacement is one of the main variables that influence the outcomes of this surgery, and several methods have been implemented to reduce it. The aim of the study is to quantify the change in haematocrit and haemoglobin at 24hours post-surgery in patients subjected to a total primary knee replacement at the Clinica Colombia between March 2016 and August 2017. Methods An observational study was conducted on a retrospective cohort. The inclusion criteria were those patients who had a total primary knee replacement with periarticular infiltration with bupivacaine, with adrenaline, ketorolac, and morphine, and intra-articular with tranexamic acid. Haemoglobin and pre- and post-operative haematocrit, blood loss calculation, and transfusions were measured. Results The analysis included a total of 159 total knee replacements (75 conventional prostheses, 84 navigated prostheses). The percentage of transfusion was 0.69% (1 patient). The decrease in mean haematocrit was 7.36%, and the mean decrease in haemoglobin was 2.49g / dl for a calculated blood loss of 780ml. A tourniquet was used in 147 patients. Discussion The combination of tourniquet use, periarticular, and intra-articular injection of tranexamic acid reduces blood loss and the need for tranfusions.

High-dose (3 g) topical tranexamic acid has higher potency in reducing blood loss after total knee arthroplasty compared with low dose (500 mg): a double-blind randomized controlled trial.

BACKGROUND: Topical intra-articular tranexamic acid (IA-TXA) has been proven to be safe and effective in reducing postoperative blood loss after primary total knee arthroplasty (TKA). The objective of this study was to investigate the efficacy of high dose (3 g) compared with low dose (500 mg) of IA-TXA in postoperative blood loss after primary TKA. METHODS: A double-blind randomized controlled trial was conducted in 80 patients who had undergone primary TKA. The patients were divided into two groups according to intra-articular TXA doses: high-dose group (3 g IA-TXA) and low-dose group (500 mg IA-TXA). The drug was injected into the joint capsule after fascial closure without suction drainage. The primary outcomes were maximum hemoglobin drop (g/dL) and calculated total blood loss (mL). Postoperative blood transfusions, thromboembolic events and functional outcomes were also recorded. RESULTS: The mean maximum hemoglobin drop was 1.3 g/dL lower in 3 g IA-TXA group compared to the 500 mg IA-TXA group [1.7 vs 3.0 g/dL, 95% confidence interval (CI) 0.9-1.7 g/dL, P < 0.001]. The 3 g IA-TXA group had 370 mL less calculated total blood loss compared to the 500 mg IA-TXA group (551 vs 921 mL, 95% CI 252-489 mL, P < 0.001). One patient in the 500 mg IA-TXA group required transfusion, while no patient in the 3 g IA-TXA group received transfusion (P = 0.31). Any thromboembolic event was not found, and functional outcome was similar between the two groups. CONCLUSIONS: Application of high-dose, 3 g topical IA-TXA was 43% more effective in reducing postoperative blood loss compared with low dose of 500 mg in primary TKA. Optimal doses in between the above two doses may be a worthwhile further investigation.